17min chapter

In Good Company with Nicolai Tangen cover image

Rerun: Lars Fruergaard Jørgensen CEO of Novo Nordisk

In Good Company with Nicolai Tangen

CHAPTER

Innovations and Challenges in Obesity Treatment

This chapter explores the advances in obesity treatment through a novel GLP-1 medication developed by a long-established diabetes-focused pharmaceutical company. It addresses the complexities of ensuring accessibility and affordability for patients in different economic regions, particularly in the U.S. versus Europe, and highlights the financial motivations driving innovation in healthcare. The conversation underscores the importance of maintaining medical oversight and addressing regulatory challenges to enhance patient access to innovative treatments.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode